Amphastar’s newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar ...

The FDA has approved the first generic equivalent of Glucagon Emergency Kit (Lilly), according to Amphastar Pharmaceuticals. Amphastar Pharmaceuticals announced that the Food and Drug ...

The FDA determined that Amphastar Pharmaceuticals' Glucagon for Injection Emergency Kit, 1 mg, a synthetic peptide product, is bioequivalent and therapeutically equivalent to Eli Lilly's ...

Amphastar gained share in this market rapidly, and we expect the company to cede share in short order. Glucagon has two primary markets: retail, in which diabetics carry glucagon emergency kits to ...

The generic glucagon (Amphastar Pharmaceuticals Inc.) is packaged as a 1 mg vial emergency kit. In its approval, the FDA found the generic glucagon to be bioequivalent and therapeutically ...

Baqsimi will give Amphastar a second emergency product for severe hypoglycemia. The company already markets a generic version of injectable glucagon for emergency kits. “The acquisition of ...

Amphastar Pharmaceuticals ... REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with ...

The FDA announced approval of Amphastar Pharmaceuticals Inc's AMPH generic glucagon for injection USP, 1mg/vial packaged in emergency kit for the treatment of hypoglycemia, which may occur in ...

The format is potentially more convenient than traditional glucagon kits from the likes of Fresenius Kabi and Amphastar ... blood glucose don’t carry an emergency kit. Supported by Xeris ...

Fresenius Kabi announced the launch of Glucagon Emergency Kit for the treatment of severe hypoglycemic episodes in adult and pediatric patients with diabetes. Fresenius Kabi announced the launch ...